Tyrosine News and Research

RSS

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Researchers identify triple mechanism that prevents onset of chromosomal instability

Universitat Autònoma de Barcelona researchers have identified for the first time the triple mechanism that stops chromosome separation in response to situations that compromise the integrity of the genetic information. The loss of this response capacity is characteristic of cancerous cells.

18 Sep 2015

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study.

17 Sep 2015

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Researchers in Japan have shown that several different classes of antidepressants increase early growth responses in astrocytes, star-shaped glial cells, which could help develop new treatments.

16 Sep 2015

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

15 Sep 2015

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life-threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

11 Sep 2015

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.

11 Sep 2015

Inhibition of Tyk2 enzyme promotes anti-cancer activity

Tyrosine kinase 2 (Tyk2) is an enzyme involved in intracellular signalling and has an important role in activating the immune system.

11 Sep 2015

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.

10 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015

People who eat high protein foods have lower blood pressure and arterial stiffness

Eating foods rich in amino acids could be as good for your heart as stopping smoking or getting more exercise - according to new research from the University of East Anglia.

27 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

Tyrosine News and Research

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Researchers identify triple mechanism that prevents onset of chromosomal instability

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Inhibition of Tyk2 enzyme promotes anti-cancer activity

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

AstraZeneca presents lung cancer research data at WCLC 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

People who eat high protein foods have lower blood pressure and arterial stiffness

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

CML survey reveals patient TKI adherence, disease anxiety

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

TKI outcomes ‘unfavourable’ in young CML patients

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

CML survey reveals patient TKI adherence, disease anxiety

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News